{"nctId":"NCT01094886","briefTitle":"Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement","startDateStruct":{"date":"2010-03"},"conditions":["Arthritis","Osteoarthritis, Knee","Osteoarthritis, Hip","Thromboembolism"],"count":56,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban"]}],"interventions":[{"name":"Rivaroxaban","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Undergone elective total hip or knee replacement surgery\n* Received postoperative venous blood clot prevention therapy within 24 hours of the surgery\n* Currently prescribed enoxaparin 30mg subcutaneous (SQ) twice a day or 40mg SQ daily for venous blood clotting prevention with an expected duration of continued prevention therapy of at least 3 days after admission to a subacute unit\n* Discharged from the hospital to a subacute unit (including skilled nursing facilities and rehabilitation units) and committed to remaining in the unit for the duration of the Pharmacodynamic blood sampling period of the study\n\nExclusion Criteria:\n\n* Platelet count \\<90,000/ÂµL based on screening laboratory assessments\n* active internal bleeding or high risk of bleeding\n* history of, or condition associated with, increased bleeding risk including\n* planned invasive procedure with potential for uncontrolled bleeding, including major surgery\n* sustained uncontrolled high blood pressure, defined as systolic blood pressure =180 mmHg or diastolic blood pressure =100 mmHg\n* clinically significant kidney disease and/or impaired kidney function\n* clinically significant liver disease\n* anemia\n* known allergies, hypersensitivity, or intolerance to rivaroxaban\n* indication for anticoagulant (blood thinning) therapy for a condition other than blood clot prevention\n* anticipated need for treatment with a prescription or nonprescription non-steroidal anti-inflammatory drugs (NSAIDs)\n* any patient who has taken more than one or two doses of aspirin (\\>100 mg/dose) in the week prior to enrollment will not be allowed to participate\n* Drug addiction or alcohol abuse within 3 years prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa)","description":"Descriptive statistics for per-patient maximum Anti-Factor Xa laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"0.422"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":"0.305"}]}]}]},{"type":"PRIMARY","title":"Summary of Change From Day 3 to Day 1 in Maximum Prothrombin Time","description":"Descriptive statistics for per-patient maximum prothrombin time laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.57","spread":"3.405"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.51","spread":"3.179"}]}]}]},{"type":"SECONDARY","title":"Summary of Change From Day 1 to Day 3 in Area Under the Curve (AUC) of aFXa","description":"Descriptive statistics for Area Under the Curve (AUC) on Study Day 1 and Day 3 for Anti-Factor Xa, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.35","spread":"7.086"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.74","spread":"7.17"}]}]}]},{"type":"SECONDARY","title":"Summary of Change From Day 1 to Day 3 in AUC of Prothrombin Time","description":"Descriptive statistics for AUC on Study Day 1 and Day 3 for prothrombin time, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"420.46","spread":"44.361"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391.37","spread":"42.664"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":53},"commonTop":["Constipation","Nausea","Asthenia","Pyrexia","Blood Iron Decreased"]}}}